An official website of the United States government
Home
Name
Sunitinib maleate
Alternate Names
SU 11248
SU-11248
SU011248
SU11248
Sutent
Abbreviations
None
Category
Chemotherapy
Subcategory
Angiogenesis inhibitor
NSC Number
736511
Primary Site
Histology
None
Remarks
Nov. 16, 2017: FDA approved Sutent (sunitinib) for the adjuvant treatment of adult patients with high risk of recurrent renal cell carcinoma following nephrectomy.
May 20, 2011 FDA approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or have spread to other parts of the body (metastatic).
FDA approved 2006 GIST, renal; Phase II urothelial, breast, stomach 2007
Pfizer.
May 20, 2011 FDA approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or have spread to other parts of the body (metastatic).
FDA approved 2006 GIST, renal; Phase II urothelial, breast, stomach 2007
Pfizer.
Coding
This drug should be coded
